Oculis Holding
Most recent annual filing: 2026-03-04
- Privosegtor PIONEER-3 trial startmid-2026Privosegtor PIONEER-3 trial start, mid-2026, routine
- Privosegtor IND filing2H 2026Privosegtor IND filing, 2H 2026, notable
- Licaminlimab pivotal topline4Q 2026Licaminlimab pivotal topline, 4Q 2026, thesis-defining
- Privosegtor pivotal readout2027Privosegtor pivotal readout, 2027, material
- ACT-02 strategic reviewMar 31, 2027ACT-02 strategic review, Mar 31, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Privosegtor
OCS-05 · ACT-01Technology platforms
OPTIREACH
Proprietary cyclodextrin-based solubilizing formulation technology that improves solubility of lipophilic drugs, increases residence time on the eye surface, and enables topical delivery of therapeutics to the posterior segment of the eye; focus area: ophthalmic diseases including DME
Discontinued (1)
- OCS-01 — Diabetic Macular Edema · company does not plan to pursue FDA regulatory filing following DIAMOND topline results
Biotech Distilled coverage (4)
- 2026-08-11 UPDATE: Oculis Holding AG (OCS) - They Bought the Farm 🔒 Paid
- 2026-08-07 UPDATE: Oculis Holding AG (OCS) - The Clock on PREDICT-1 Is Now Readable 🔒 Paid
- 2026-08-04 UPDATE: Oculis Holding AG (OCS) - The Neuroprotectant Gets a Bigger Door 🔒 Paid
- 2026-06-05 Oculis Holding AG (OCS) — Scientific Deep Dive for Privosegtor, Licaminlimab, and the OCS-01 Wreckage
Articles open on Substack. Some deep dives are subscriber-only.